Jee-Soo Lee, Eun Hye Cho, Boram Kim, Jinyoung Hong, Young-Gon Kim, Yoonjung Kim, Ja-Hyun Jang, Seung-Tae Lee, Sun-Young Kong, Woochang Lee, Saeam Shin, Eun Young Song
Circulating tumor DNA (ctDNA) has emerged as a promising tool for various clinical applications, including early diagnosis, therapeutic target identification, treatment response monitoring, prognosis evaluation, and minimal residual disease detection. Consequently, ctDNA assays have been incorporated into clinical practice. In this review, we offer an in-depth exploration of the clinical implementation of ctDNA assays. Notably, we examined existing evidence related to pre-analytical procedures, analytical components in current technologies, and result interpretation and reporting processes...
January 15, 2024: Annals of Laboratory Medicine